ATP13A2
Basic information
Region (hg38): 1:16985958-17011928
Previous symbols: [ "PARK9" ]
Links
Phenotypes
GenCC
Source:
- autosomal recessive spastic paraplegia type 78 (Moderate), mode of inheritance: AR
- Kufor-Rakeb syndrome (Strong), mode of inheritance: AR
- autosomal recessive spastic paraplegia type 78 (Strong), mode of inheritance: AR
- parkinsonism due to ATP13A2 deficiency (Supportive), mode of inheritance: AR
- autosomal recessive spastic paraplegia type 78 (Supportive), mode of inheritance: AR
- Kufor-Rakeb syndrome (Moderate), mode of inheritance: AR
- Kufor-Rakeb syndrome (Definitive), mode of inheritance: AR
- Kufor-Rakeb syndrome (Strong), mode of inheritance: AR
- autosomal recessive spastic paraplegia type 78 (Strong), mode of inheritance: AR
- Kufor-Rakeb syndrome (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Kufor-Rakeb syndrome (Parkinson disease 9) | AR | Neurologic | In Kufor-Rakeb syndrome, response to levodopa has been documented | Neurologic | 16964263; 17485642; 20310007; 22388936; 27217339 |
ClinVar
This is a list of variants' phenotypes submitted to
- Kufor-Rakeb syndrome;Autosomal recessive spastic paraplegia type 78 (21 variants)
- Autosomal recessive spastic paraplegia type 78;Kufor-Rakeb syndrome (5 variants)
- Inborn genetic diseases (4 variants)
- Autosomal recessive spastic paraplegia type 78 (3 variants)
- not provided (3 variants)
- Kufor-Rakeb syndrome (3 variants)
- Neurodegeneration with brain iron accumulation (1 variants)
- ATP13A2-related disorder (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the ATP13A2 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 10 | 194 | 211 | |||
missense | 385 | 27 | 417 | |||
nonsense | 11 | 19 | ||||
start loss | 1 | |||||
frameshift | 19 | 32 | ||||
inframe indel | 6 | |||||
splice donor/acceptor (+/-2bp) | 13 | 14 | ||||
splice region | 1 | 21 | 30 | 1 | 53 | |
non coding | 15 | 142 | 24 | 181 | ||
Total | 30 | 29 | 425 | 363 | 34 |
Highest pathogenic variant AF is 0.0000329
Variants in ATP13A2
This is a list of pathogenic ClinVar variants found in the ATP13A2 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
1-16985970-T-C | Kufor-Rakeb syndrome | Likely benign (Jun 14, 2016) | ||
1-16985978-T-G | Kufor-Rakeb syndrome | Uncertain significance (Jan 13, 2018) | ||
1-16985990-C-T | Kufor-Rakeb syndrome • ATP13A2-related disorder | Benign (Apr 01, 2024) | ||
1-16986014-G-A | not specified | Uncertain significance (Jun 15, 2023) | ||
1-16986039-G-A | Kufor-Rakeb syndrome | Uncertain significance (Jan 12, 2018) | ||
1-16986063-A-C | Likely benign (Aug 01, 2022) | |||
1-16986063-A-G | Kufor-Rakeb syndrome | Likely benign (Jul 01, 2024) | ||
1-16986065-C-T | Uncertain significance (Nov 01, 2023) | |||
1-16986066-G-A | Kufor-Rakeb syndrome • Kufor-Rakeb syndrome;Autosomal recessive spastic paraplegia type 78 | Conflicting classifications of pathogenicity (Dec 01, 2022) | ||
1-16986069-T-TC | Uncertain significance (Jan 01, 2020) | |||
1-16986075-G-A | ATP13A2-related disorder | Likely benign (Mar 07, 2019) | ||
1-16986076-G-A | Inborn genetic diseases | Uncertain significance (Nov 24, 2021) | ||
1-16986081-G-C | Kufor-Rakeb syndrome • ATP13A2-related disorder | Benign/Likely benign (Sep 16, 2019) | ||
1-16986083-G-A | Inborn genetic diseases | Uncertain significance (Aug 25, 2022) | ||
1-16986091-G-A | Kufor-Rakeb syndrome • Kufor-Rakeb syndrome;Autosomal recessive spastic paraplegia type 78 | Conflicting classifications of pathogenicity (Aug 01, 2024) | ||
1-16986097-G-A | Kufor-Rakeb syndrome | Benign (Jul 17, 2018) | ||
1-16986101-T-A | Kufor-Rakeb syndrome • ATP13A2-related disorder | Benign/Likely benign (Mar 01, 2024) | ||
1-16986112-G-A | See cases | Uncertain significance (Apr 05, 2020) | ||
1-16986142-G-A | Uncertain significance (Dec 01, 2017) | |||
1-16986145-G-A | Uncertain significance (May 14, 2020) | |||
1-16986163-T-C | Kufor-Rakeb syndrome | Uncertain significance (Jan 13, 2018) | ||
1-16986172-T-C | Uncertain significance (Jan 01, 2024) | |||
1-16986180-A-G | ATP13A2-related disorder | Likely benign (Feb 15, 2021) | ||
1-16986190-T-C | ATP13A2-related disorder | Likely benign (Aug 27, 2024) | ||
1-16986197-G-A | Kufor-Rakeb syndrome | Uncertain significance (Apr 01, 2017) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
ATP13A2 | protein_coding | protein_coding | ENST00000326735 | 29 | 25971 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
8.96e-9 | 1.00 | 125647 | 0 | 101 | 125748 | 0.000402 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 1.40 | 624 | 731 | 0.854 | 0.0000508 | 7465 |
Missense in Polyphen | 186 | 241.28 | 0.7709 | 2622 | ||
Synonymous | -0.537 | 342 | 330 | 1.04 | 0.0000243 | 2564 |
Loss of Function | 4.12 | 24 | 57.8 | 0.415 | 0.00000289 | 620 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000909 | 0.000902 |
Ashkenazi Jewish | 0.00249 | 0.00248 |
East Asian | 0.000273 | 0.000272 |
Finnish | 0.000102 | 0.0000924 |
European (Non-Finnish) | 0.000321 | 0.000316 |
Middle Eastern | 0.000273 | 0.000272 |
South Asian | 0.000201 | 0.000196 |
Other | 0.000818 | 0.000815 |
dbNSFP
Source:
- Function
- FUNCTION: ATPase that plays a role in intracellular cation homeostasis and the maintenance of neuronal integrity (PubMed:22186024). Required for a proper lysosomal and mitochondrial maintenance (PubMed:22296644, PubMed:28137957). {ECO:0000269|PubMed:22186024, ECO:0000269|PubMed:22296644, ECO:0000269|PubMed:28137957}.;
- Disease
- DISEASE: Kufor-Rakeb syndrome (KRS) [MIM:606693]: A rare form of autosomal recessive juvenile or early-onset, levodopa-responsive parkinsonism. In addition to typical parkinsonian signs, clinical manifestations of Kufor-Rakeb syndrome include behavioral problems, facial tremor, pyramidal tract dysfunction, supranuclear gaze palsy, and dementia. {ECO:0000269|PubMed:16964263, ECO:0000269|PubMed:17485642, ECO:0000269|PubMed:18413573, ECO:0000269|PubMed:20683840, ECO:0000269|PubMed:20853184, ECO:0000269|PubMed:21542062, ECO:0000269|PubMed:22296644, ECO:0000269|PubMed:22388936, ECO:0000269|PubMed:22768177, ECO:0000269|PubMed:28137957}. Note=The disease is caused by mutations affecting the gene represented in this entry. KRS has also been referred to as neuronal ceroid lipofuscinosis 12 (CLN12), due to neuronal and glial lipofuscin deposits detected in the cortex, basal nuclei and cerebellum of some patients. {ECO:0000269|PubMed:22388936}.; DISEASE: Spastic paraplegia 78, autosomal recessive (SPG78) [MIM:617225]: A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. {ECO:0000269|PubMed:27217339, ECO:0000269|PubMed:28137957}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Ion channel transport;Transport of small molecules;Ion transport by P-type ATPases
(Consensus)
Recessive Scores
- pRec
- 0.161
Intolerance Scores
- loftool
- 0.0289
- rvis_EVS
- -1.16
- rvis_percentile_EVS
- 6.1
Haploinsufficiency Scores
- pHI
- 0.160
- hipred
- Y
- hipred_score
- 0.563
- ghis
- 0.568
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.227
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Atp13a2
- Phenotype
- cellular phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); hematopoietic system phenotype; pigmentation phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); immune system phenotype;
Zebrafish Information Network
- Gene name
- atp13a2
- Affected structure
- whole organism
- Phenotype tag
- abnormal
- Phenotype quality
- increased curvature
Gene ontology
- Biological process
- cellular calcium ion homeostasis;cellular iron ion homeostasis;cellular zinc ion homeostasis;regulation of mitochondrion organization;regulation of macroautophagy;regulation of autophagosome size;cellular cation homeostasis;regulation of intracellular protein transport;ion transmembrane transport;cellular response to oxidative stress;protein autophosphorylation;positive regulation of protein secretion;regulation of endopeptidase activity;zinc ion homeostasis;cellular response to manganese ion;cellular response to zinc ion;extracellular exosome biogenesis;ATP hydrolysis coupled cation transmembrane transport;negative regulation of neuron death;polyamine transmembrane transport;regulation of autophagy of mitochondrion;positive regulation of exosomal secretion;regulation of chaperone-mediated autophagy;autophagosome organization;regulation of glucosylceramidase activity;regulation of lysosomal protein catabolic process;negative regulation of lysosomal protein catabolic process;peptidyl-aspartic acid autophosphorylation
- Cellular component
- lysosome;lysosomal membrane;late endosome;multivesicular body;autophagosome;vesicle membrane;integral component of membrane;transport vesicle;vesicle;multivesicular body membrane;neuron projection;neuronal cell body;lysosomal lumen;integral component of lysosomal membrane
- Molecular function
- protein binding;ATP binding;zinc ion binding;ATPase activity;cation-transporting ATPase activity;manganese ion binding;phosphatidic acid binding;phosphatidylinositol-3,5-bisphosphate binding;cupric ion binding